- Home
- IRON vs ARKO Comparison
IRON vs ARKO Comparison
Compare IRON & ARKO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- ARKO
- Stock Information
- Founded
- IRON 2017
- ARKO 1970
- Country
- IRON United States
- ARKO United States
- Employees
- IRON N/A
- ARKO N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- ARKO Oil Refining/Marketing
- Sector
- IRON Health Care
- ARKO Energy
- Exchange
- IRON Nasdaq
- ARKO Nasdaq
- Market Cap
- IRON 1.9B
- ARKO N/A
- IPO Year
- IRON N/A
- ARKO N/A
- Fundamental
- Price
- IRON $57.83
- ARKO $6.54
- Analyst Decision
- IRON Strong Buy
- ARKO Hold
- Analyst Count
- IRON 10
- ARKO 2
- Target Price
- IRON $73.70
- ARKO $6.13
- AVG Volume (30 Days)
- IRON 245.9K
- ARKO 298.9K
- Earning Date
- IRON 11-12-2024
- ARKO 02-25-2025
- Dividend Yield
- IRON N/A
- ARKO 1.85%
- EPS Growth
- IRON N/A
- ARKO N/A
- EPS
- IRON N/A
- ARKO 0.16
- Revenue
- IRON N/A
- ARKO $8,973,013,000.00
- Revenue This Year
- IRON N/A
- ARKO N/A
- Revenue Next Year
- IRON N/A
- ARKO N/A
- P/E Ratio
- IRON N/A
- ARKO $41.09
- Revenue Growth
- IRON N/A
- ARKO N/A
- 52 Week Low
- IRON $25.60
- ARKO $4.09
- 52 Week High
- IRON $77.60
- ARKO $8.39
- Technical
- Relative Strength Index (RSI)
- IRON 37.45
- ARKO 46.00
- Support Level
- IRON $57.09
- ARKO $6.12
- Resistance Level
- IRON $62.20
- ARKO $6.62
- Average True Range (ATR)
- IRON 2.88
- ARKO 0.24
- MACD
- IRON -0.82
- ARKO -0.02
- Stochastic Oscillator
- IRON 8.16
- ARKO 65.62
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.